Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on CG Oncology, Inc.. The associated price target remains the same with $82.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors including the recent legal victory for CG Oncology, Inc. The company successfully defended itself against a lawsuit by ANI Pharmaceuticals, which means it will not have to pay a 5% royalty on future sales of cretostimogene. This favorable outcome was already anticipated in Slutsky’s financial model, so it does not alter the price target for CG Oncology’s stock.
Additionally, the company has several promising milestones on the horizon, such as the expected topline data from the BOND-003 and CORE-008 studies in the second half of 2025, and the filing of a Biologics License Application (BLA) for cretostimogene. These upcoming developments, along with the company’s current financial metrics, contribute to the positive outlook and Buy rating for CG Oncology’s stock.
In another report released on July 16, RBC Capital also maintained a Buy rating on the stock with a $53.00 price target.